Adocia Logo

Adocia

ISIN: FR0011184241 | Ticker: ADOC | LEI: 969500ZL79KYH9PTYP78
Sector: Health CareSub-Industry: Biotechnology
Country: France

About Adocia

Company Description

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases.

In the diabetes field, Adocia’s portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring five clinical-stage products. Additionally, Adocia aims to expand its portfolio towards the treatment of other metabolic diseases and their comorbidities.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application.

Year founded

2005

Served area

Worldwide

Headquarters

115 Avenue Lacassagne, 69003 Lyon – France

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 45,166,000.00 30,054,000.00 30,613,000.00
Noncurrent Assets N/A 8,720,000.00 1,073,000.00 4,353,000.00
Land N/A 2,032,000.00 0.00 0.00
Buildings N/A 3,298,000.00 0.00 2,050,000.00
Other Property Plant And Equipment N/A 2,502,000.00 642,000.00 492,000.00
Goodwill N/A 0.00 0.00 0.00
Other Intangible Assets N/A 46,000.00 3,000.00 32,000.00
Current Assets N/A 36,446,000.00 22,084,000.00 26,260,000.00
Current Trade Receivables N/A 0.00 207,000.00 467,000.00
Cash and cash equivalents 43,661,000.00 28,114,000.00 15,163,000.00 17,422,000.00
Noncurrent Assets Or Disposal Groups Classified As Held For Sale N/A 0.00 6,897,000.00 0.00
Other Current Assets N/A 7,763,000.00 6,197,000.00 8,234,000.00
Equity And Liabilities N/A 45,166,000.00 30,054,000.00 30,613,000.00
Equity N/A 6,334,000.00 -13,815,000.00 -12,970,000.00
Issued Capital N/A 702,000.00 727,000.00 873,000.00
Share Premium N/A 78,731,000.00 80,562,000.00 86,123,000.00
Noncurrent Liabilities N/A 28,110,000.00 20,115,000.00 18,506,000.00
Other Noncurrent Liabilities N/A 715,000.00 309,000.00 0.00
Current Liabilities N/A 10,723,000.00 23,754,000.00 25,077,000.00
Trade And Other Current Payables N/A 4,943,000.00 3,835,000.00 6,414,000.00
Other Current Liabilities N/A 2,766,000.00 3,724,000.00 2,992,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 841,000.00 1,444,000.00 11,447,000.00
Depreciation And Amortisation Expense 1,133,000.00 1,158,000.00 496,000.00
Profit Loss From Operating Activities -21,148,000.00 -19,366,000.00 -1,698,000.00
Finance Income 103,000.00 220,000.00 573,000.00
Finance Costs 2,250,000.00 3,608,000.00 5,300,000.00
Profit Loss Before Tax -23,295,000.00 -22,754,000.00 -6,425,000.00
Income Tax Expense Continuing Operations 29,000.00 0.00 476,000.00
Profit (loss) -23,324,000.00 -22,754,000.00 -6,901,000.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -23,324,000.00 -22,754,000.00 -6,901,000.00
Adjustments For Income Tax Expense N/A 0.00 0.00 0.00
Other Adjustments For Noncash Items N/A 2,650,000.00 4,791,000.00 13,045,000.00
Adjustments For Losses Gains On Disposal Of Noncurrent Assets N/A 53,000.00 27,000.00 -16,560,000.00
Cash Flows From Used In Operating Activities N/A -21,854,000.00 -19,234,000.00 -14,995,000.00
Other Inflows Outflows Of Cash Classified As Investing Activities N/A 0.00 0.00 0.00
Cash Flows From Used In Investing Activities N/A -204,000.00 -361,000.00 21,864,000.00
Proceeds From Borrowings Classified As Financing Activities N/A 7,000,000.00 6,000,000.00 6,000,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 488,000.00 398,000.00 10,611,000.00
Other Inflows Outflows Of Cash Classified As Financing Activities N/A 0.00 0.00 0.00
Cash Flows From Used In Financing Activities N/A 6,512,000.00 6,644,000.00 -4,611,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A -15,547,000.00 -12,951,000.00 2,259,000.00
Cash and cash equivalents 43,661,000.00 28,114,000.00 15,163,000.00 17,422,000.00

Please note that some sums might not add up.

Filings & Publications

2021

Report
Q1
H1
Q3
FY
Consolidated Report
FRA
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
29.12.23 None Other Sell EUR 236,550.00
05.10.23 None Other Sell EUR 400,000.00
20.09.23 None Other Sell EUR 291,376.85
28.07.23 None Other Buy EUR 999,998.56
28.07.23 None Other Buy EUR 499.40

Capital markets information

ISIN

FR0011184241

LEI

969500ZL79KYH9PTYP78

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Paris

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.